

CLAIMS

1. An immunostimulant composition comprising at least one agonist of the Toll-like 7 receptor or of the Toll-like 8 receptor, characterized in that it additionally
5 comprises an agonist of the Toll-like 4 receptor.
2. The immunostimulant composition as claimed in the preceding claim, characterized in that the agonist of the Toll-like 7 receptor or of the Toll-like 8 receptor is a compound different from the agonist of the Toll-like 4 receptor.
10
3. The immunostimulant composition as claimed in either of claims 1 and 2, characterized in that it additionally comprises at least one vaccine antigen.
4. The immunostimulant composition as claimed in one of the preceding claims, characterized in that the agonist of the Toll-like 7 receptor is an
15 imidazoquinolineamine derivative.
5. The immunostimulant composition as claimed in the preceding claim, characterized in that the imidazoquinolineamine derivative is 4-amino-
20 2-ethoxymethyl- α,α -dimethyl-1-H-imidazo[4,5c]quinoline-1-ethanol.
6. The immunostimulant composition as claimed in one of the preceding claims, characterized in that the agonist of the Toll-like 4 receptor is ER804057.
- 25 7. The use of an immunostimulant composition as claimed in one of the preceding claims, for the manufacture of a medicament.
8. The use of an immunostimulant composition as claimed in one of claims 1 to 6, for the manufacture of a medicament capable of inducing a TH1 type immune
30 response.